Novartis vet is getting another shot at mTOR following the implosion of a longevity pioneer

One of the upstarts in the longevity field has roped in some fresh discovery assets out of Novartis — along with a Novartis vet to head …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

No­var­tis vet is get­ting an­oth­er shot at mTOR fol­low­ing the im­plo­sion of a longevi­ty pi­o­neer